Eledon Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ELDN Nasdaq 8731 https://eledon.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results - Mar 28th, 2024 8:01 pm
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection - Mar 25th, 2024 8:56 pm
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human - Mar 21st, 2024 2:31 pm
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 14th, 2024 12:01 am
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook - Jan 4th, 2024 9:40 pm
Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely? - Dec 25th, 2023 10:23 am
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference - Nov 29th, 2023 9:05 pm
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results - Nov 9th, 2023 9:01 pm
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference - Nov 8th, 2023 9:05 pm
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation - Nov 2nd, 2023 1:05 pm
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer - Oct 23rd, 2023 11:00 am
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting - Oct 13th, 2023 11:00 am
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors - Oct 2nd, 2023 11:00 am
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human - Sep 25th, 2023 11:00 am
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference - Sep 20th, 2023 8:05 pm
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates - Sep 6th, 2023 11:00 am
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation - Sep 5th, 2023 11:00 am
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation - Aug 16th, 2023 11:00 am
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results - Aug 10th, 2023 11:00 am
Amerigo Reports Q2-2023 Production Results and Provides MVC Operational Update - Jul 12th, 2023 11:30 am